Spirax Group (1LNB) AI Stock Analysis
Spirax Group
(BX Swiss:1LNB)
No summary available
Spirax Group Business Overview & Revenue Model
Company Description
Spirax-Sarco Engineering plc, founded in 1888 and headquartered in Cheltenham, UK, delivers sophisticated engineered solutions across several core technological domains. The company specializes in comprehensive industrial and commercial steam systems...
Spirax Group Earnings Call Summary
The call presents a broadly positive performance: the group delivered mid‑single‑digit organic sales and profit growth, with notable margin progression in ETS and Watson‑Marlow, improved ROCE, strong order books, and reiterated medium‑term targets. Short‑term headwinds include STS margin phasing, inventory builds for geopolitical risk (reducing H1 cash conversion), temporary leverage slightly above the target range, and exposure to weak industrial production and FX movements. Management highlighted concrete operational and commercial initiatives (digital connections, decarbonization, localized production, and sales reinvestment) that support confidence in delivering full‑year guidance and medium‑term targets. Overall, the positive execution and pipeline momentum outweigh the transitory challenges communicated.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated full‑year guidance and said the group is on track, expecting higher H2 volumes and margin progression (typical adjusted operating profit weighting c.45% H1 / 55% H2). Key metrics: H1 organic sales +5% (vs IP +1.5%), organic operating profit +6%, adjusted operating margin 19.8% (up 10bps organically), adjusted EPS +9% to 150p, adjusted cash from operations £92m (H1 cash conversion 54%; full‑year cash conversion expected ~90%), H1 CapEx ~3% of sales with full‑year CapEx to be at the lower end of the 4–5% guidance, net debt £618m (net debt/EBITDA 1.6x; target 1.0–1.5x by year‑end), and ROCE >35% (up 180bps). Division outlooks: STS H1 sales +1% with stronger H2 and medium‑term margin target 23.5%; ETS H1 sales +11% with margin 17.2% (up 220bps) and a 20% margin target; Watson‑Marlow H1 sales +7% with margin 27.5% (up 80bps) and a path to >30%. FX assumed to have negligible full‑year revenue/profit impact (H1 profit had ~+2% FX tailwind; expect ~-2% H2 headwind).
Spirax Group Peers Comparison
Overall Rating
GB:IMI76Outperform
GB:ROR76Outperform
GB:BOY67Neutral
GB:WEIR65Neutral
GB:SMIN61Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | GBP 6.79B | 21.09 | 32.41% | 1.22% | 7.67% | 45.97% | |
| 76Outperform | GBP 4.02B | 33.18 | 21.48% | 1.69% | 2.22% | 25.89% | |
| 67Neutral | GBP 1.55B | 26.97 | 9.30% | 2.54% | 1.68% | 111.96% | |
| 65Neutral | GBP 6.87B | 25.78 | 13.45% | 1.60% | 5.84% | -14.62% | |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 61Neutral | GBP 7.47B | 4.31 | 92.97% | 1.79% | -33.55% | 4.29% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:BOY | Bodycote plc | 917.00 | 312.00 | 51.57% | |
| GB:IMI | IMI plc | 2890.00 | 518.36 | 21.86% | |
| GB:ROR | Rotork (ROR) | 494.00 | 161.52 | 48.58% | |
| GB:SMIN | Smiths Group plc | 2709.00 | 206.23 | 8.24% | |
| GB:WEIR | Weir Group plc (The) | 2630.00 | -219.61 | -7.71% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.